Clover Health Investments has staged a very strong three year run, yet the current checks still suggest the stock leans cheap rather than fully pricing in that shift in fortunes.
- The share price has returned about 3.3x over three years, which puts recent trading firmly in the high move bracket for this period.
- Profitability progress and Medicare Advantage membership growth can support the case for the current valuation, while higher medical costs and healthcare usage remain a clear risk to margins and earnings quality.
- The broader valuation workup, including the value score of 5 out of 6, points to Clover Health Investments looking cheap across most checks rather than fully priced.
The issue now is whether Clover Health Investments offers enough margin of safety after this run, or whether the recent gains already reflect most of the good news.
Scan beyond Clover Health Investments and spot other potential breakouts across our curated list of 32 high quality undervalued stocks.
Where Does Clover Health Investments Sit on Sales?
The P/S ratio suits Clover Health Investments because revenue is still the cleaner anchor than earnings for a recovering insurer. The current P/S multiple sits around 1.0x, which is below the broader Healthcare sector average of about 1.5x and also below the peer group near 2.1x. That means investors are paying fewer dollars for each dollar of Clover Health Investments revenue than for many comparable health stocks.
The fair P/S ratio from the model comes in slightly higher at about 1.1x. This suggests the recent share price is close to what would be expected once the company profile, risk mix and sector are all factored in. Despite recent profit headlines and membership momentum, the market multiple still points to Clover Health Investments trading near a reasonable range rather than at a clear discount or a stretched premium.
On the preferred P/S yardstick, Clover Health Investments now appears roughly fairly valued relative to what the fundamentals and risk profile would suggest.
See what the numbers say about this price — find out in our valuation breakdown.
The Clover Health Investments Narrative: What Would Justify Today's Price?
Clover Health Investments' valuation puzzle naturally raises the question of which future paths would justify a meaningfully different share price from here. That is where Simply Wall St Narratives step in as a structured bridge between today’s multiples and tomorrow’s outcomes on growth, margins and earnings. Rather than leaning on a single model output, each narrative lays out the key assumptions behind its view of fair value so you can compare those expectations with the actual numbers as results and updates arrive on the Community page.
One of the top community narratives on Clover Health Investments: 7% undervalued
"The company's differentiated technology-driven care model, particularly the Clover Assistant platform, positions it to benefit from the healthcare industry's accelerated shift toward technology adoption and data-driven, value-based care..."
Read one of the top narratives on Clover Health Investments
Do you think there's more to the story for Clover Health Investments? Head over to our Community to see what others are saying!
The Bottom Line
Clover Health Investments now trades on a P/S that lines up closely with sector and peer benchmarks, so the easy valuation gap looks largely closed. The broader checks still lean supportive, which keeps the door open for upside if execution on margins and membership quality holds together. The real fault line between bulls and bears is simple. It comes down to whether the insurer can keep medical costs in check enough for today’s roughly fair multiple to turn into genuine value rather than a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com